UK MHRA accepts marketing application for almetinib

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

UK MHRA accepts marketing application for almetinib

• Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
• Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
• FDA has mandated a top-level black box warning for all marketed CAR-T therapies
• Can people with high blood pressure eat peanuts?
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

UK MHRA accepts marketing application for almetinib.

On June 14, EQRx, Inc announced that the UK Medicines and Health Products Regulatory Agency (MHRA) has accepted a Marketing Authorization Application (MAA) for the third-generation EGFR tyrosine kinase inhibitor (TKI) almetinib for the treatment of adults First-line treatment of locally advanced or metastatic non-small cell lung cancer.

The application is primarily based on data from the pivotal Phase III AENEAS trial, which is the first time EQRx has submitted a marketing application to a regulatory agency.

AENEAS (NCT03849768) is a randomized, double-blind, multicenter Phase III study to evaluate the efficacy and safety of almetinib versus gefitinib as first-line treatment for adults with locally advanced or metastatic EGFR-mutant non-small cell lung cancer sex.

Conducted by Hansoh Pharmaceuticals, the study enrolled 429 patients who were randomized to receive almetinib (n=214) or gefitinib (n=215). The study met its primary endpoint, data have been published in the Journal of Clinical Oncology, and data on almetinib activity in CNS metastases were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.